度伐利尤单抗致反应性皮肤毛细血管增生症1例

Reactive cutaneous capillary endothelial proliferation induced by durvalumab:a case report

目的 分析度伐利尤单抗致反应性皮肤毛细血管增生症(RCCEP)1例,提示临床需重视度伐利尤单抗引起的新型免疫相关不良反应。方法 分析1例晚期肺癌患者使用度伐利尤单抗期间出现RCCEP的病例,并结合文献阐述度伐利尤单抗引起RCCEP的可能原因。结果 本例患者出现RCCEP可能是度伐利尤单抗所致。服用阿帕替尼后,患者RCCEP症状得到缓解。结论 加强度伐利尤单抗使用期间的用药监护及用药教育,定期观察患者的皮肤情况,及时准确地获取患者相关症状,并施以针对性治疗方案,可有效避免患者不良反应症状加重。

Objective To analyze one case of reactive cutaneous capillary endothelial proliferation(RCCEP)induced by durvalumab,in order to call clinical attention to new immune-related adverse events(irAEs).Methods One case of RCCEP occurred in a patient with advanced lung cancer during the use of durvalumab was analyzed,and the possible causes of RC-CEP induced by durvalumab were described by combining the literature review.Results This case of RCCEP was likely in-duced by durvalumab.After treated with apatinib,the symptoms of RCCEP were relieved.Conclusion The clinical use of durvalumab should be monitored more vigorously,and drug use education should be strengthened.It is also necessary to ob-serve the skin condition of patients regularly,to obtain timely and accurately the relevant symptoms of patients,and to give targeted treatment plans,so that can effectively avoid the aggravation of the adverse reaction symptoms of patients.